Pembrolizumab Plus Reduced-dose Ipilimumab Safe in Advanced Melanoma

Patients with advanced melanoma may have good outcomes when treated with standard-dose pembrolizumab with 4 doses of reduced-dose ipilimumab, according to a study published in The Lancet Oncology.

Medicare, insurance beneficiaries have improved access to uveal melanoma test

Three important access milestones for DecisionDx-UM have been reached, Castle Biosciences announced in a press release.

Personalized Cancer Vaccines Demonstrate Potential in Melanoma Studies

NEW YORK (GenomeWeb) – A pair of new studies is pointing to the potential of personalized anti-cancer vaccine strategies in individuals with advanced melanoma.

Link between Parkinson’s and melanoma runs both ways

A study published this week in Mayo Clinic Proceedings confirms that Parkinson’s disease can, perhaps surprisingly, increase the risk of melanoma.

Cancer in the News

Feature Articles

Parkinson disease appears linked to melanoma

Source: Healio, July 2017 Patients with Parkinson disease or melanoma each had increased risk for the other disease, according to results of a retrospective cohort study. These results suggest a prevalent association between the two diseases, according to the researchers. “If we can pinpoint the cause of the association between Parkinson disease and melanoma, we […]

Read the full story

Posted in Melanoma In The News, Information

Personalized Cancer Vaccines Look Promising in Two New Studies

A vaccine that teaches the body to selectively destroy tumors has eluded cancer researchers for decades. Despite many clinical trials, such vaccines have shown little to no success.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Researchers’ neural network model can predict melanoma from images with a high degree of accuracy

It’s a mark on your skin you’ve never noticed before. It’s a spot with irregular borders, or a mole that seems to be changing. Maybe it’s a wound that does not heal.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Nivolumab extends survival in resected, high-risk melanoma

Nivolumab prolonged RFS compared with ipilimumab among patients with advanced melanoma who had undergone resection, according to an interim analysis of a randomized phase 3 trial.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories